New study backs C2N’s PrecivityAD2 test in symptomatic patients

New peer-reviewed data reinforce that C2N’s PrecivityAD2™ blood test offers high accuracy in detecting brain amyloid pathology in patients with cognitive symptoms. According to the company, the test achieved 91 % accuracy, 90 % sensitivity, and 92 % specificity when compared against amyloid PET imaging as the reference standard. Published in npj Dementia, the research […] The post New study backs C2N’s PrecivityAD2 test in symptomatic patients appeared first on Longevity.Technology.